Daniel Parera is a physician-entrepreneur turned investor at Kurma Partners who brings hands-on clinical and operational founder experience to growth-stage investing, specializing in the Kurma Growth Opportunities strategy that focuses on later-stage European life sciences companies. Based in Munich, he serves as a bridge between German-speaking biotech ecosystems and Kurma's broader European platform, with particular expertise in radiopharmaceuticals and oncology demonstrated through his board role at Nuclidium following Kurma's co-leadership of an €84m financing.
About their Fund
Kurma Partners operates two specialized healthcare franchises under one roof—Kurma Biofund for therapeutics and biotech company creation from academic labs, and Kurma Diagnostics for diagnostics and digital health—while offering a full innovation-to-growth continuum through its dedicated Growth Opportunities Fund that continues financing promising portfolio companies into scale-up rounds. The firm has built a systematic company-creation engine with major European research institutes like Institut Pasteur and VIB, spinning out academic research into venture-backed companies and providing portfolio companies with operational support through strategic partnerships like its alliance with Samsung Biologics for development and manufacturing capabilities.
















.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)




















































































